Drug Profile
Research programme: interleukin-12/STAT4 transcription factor inhibitors - Diakine Therapeutics
Alternative Names: C-9; DT 22669; DT 23552; ISLT-2669; ISLT-LSF analogs; ISLT-LSF analogues; Lisofylline analogs; Lisofylline analoguesLatest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator University of Virginia
- Developer DiaKine Therapeutics; National Institute of Diabetes and Digestive and Kidney Diseases
- Class Small molecules
- Mechanism of Action Immunomodulators; Interleukin 12 inhibitors; STAT4 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic nephropathies; Diabetic retinopathy; Latent autoimmune diabetes in adults; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Diabetic-nephropathies in USA (PO)
- 28 Dec 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (PO)
- 28 Dec 2017 No recent reports of development identified for preclinical development in Latent-autoimmune-diabetes-in-adults in USA (PO)